Real-world efficacy of baricitinib among patients with severe and critical COVID-19 pneumonia admitted in Ospital ng Makati from December 2020 to May 2021: A case-control study
- Author:
Aldrin J. Corañez
1
;
Ryan Paul Fernandez
1
;
Maria Czarina Poquiz
1
;
Edlyn John Santos
1
;
Evan Vista
1
Author Information
- Publication Type:Journal Article
- Keywords: Baricitinib; Tocilizumab
- MeSH: COVID-19; Standard of Care
- From: Philippine Journal of Internal Medicine 2024;62(2):77-82
- CountryPhilippines
- Language:English
-
Abstract:
Background:Management of COVID--19 patients during surges have been a challenge as hospitals have to deal with staff,
room, and medication shortages. Among these medications is tocilizumab which is given to patients with severe/critical
conditions. In Ospital ng Makati, patients are given baricitinib as alternative immunomodulator to prevent possible cytokine
storm during tocilizumab shortages. The current recommendation for baricitinib is to give it in addition to dexamethasone
and remdesivir for hospitalized COVID-19 patients requiring low to high-flow oxygen, and non-invasive ventilation.
However, there is not enough evidence to recommend it as an alternative to tocilizumab in COVID--19 patients. This study
aims to find out the real-world efficacy of baricitinib in addition to standard of care among admitted patients with severe
COVID-19 pneumonia admitted in Ospital ng Makati.
Methods:This is a retrospective, case control study that reviewed records of adult patients admitted at Ospital ng Makati from December 2020 to May 2021 due to severe COVID-19. Patients who were given standard of care was compared to those who were given baricitinib by measuring the duration of clinical improvement, in-hospital all-cause mortality, number of hospital stay, and progression to acute respiratory distress syndrome (ARDS) and need for mechanical ventilator.
Results:The use of baricitinib led to a faster improvement time (10 vs 12 days) however did not reach level of significance (p=0.069). There was also no significant difference in the mortality, number of hospital days, and progression to ARDS between the two groups.
Conclusion:There is not enough evidence to recommend baricitinib as an alternative to tocilizumab in patients with severe COVID--19 infection. - Full text:20240627114938507701 2022-205 OK.pdf
